- State of the market: Are generic drugs approaching their peak?
- Teva launches authorized generic version of Pfizer's Detrol LA
- Reports: Three drug makers have sights on Pfizer's generics unit
- Lipitor may be the first statin to switch to OTC
- NACDS, NCPA, GPhA express support for Drug Quality and Security Act
NEEDHAM, Mass. Pfizer is pulling out of a development deal for a potential brain cancer drug, saying it is not a strategic priority, according to the drug's developer Celldex Therapeutics.
Celldex said it will regain full worldwide rights to develop and sell rindopepimut from Pfizer. The drug candidate also is called CDX-110. In May, the company reported positive results form a midstage study on the drug.
Celldex will regain rights to the drug candidate on Nov. 1.